CHCWM – Cancer & Hematology Centers of West Michigan

INBRX-106 (InhibRx)

DescriptionAn Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors

Mechanism of Action:  Agonist of OX 40 (T cell co-stimulatory molecule)

Target Patient Population:  Single agent Cohort for Renal Cell, , Gastric/GEJ, Urothelial, Combination with Pembrolizumab cohort for Gastric, Renal Cell, Non Small Cell Lung, Melanoma, Head & Neck and Nasopharyngeal

Study Design:  Drug is given IV every 3 weeks